Spending and Utilization for Chronic Rhinosinusitis With Nasal Polyps Therapies Among Commercially Insured Beneficiaries.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40026190.
- Also identified by DOI 10.1002/lary.32063 and PMC identifier 11980964.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Food and Drug Administration (FDA) recently approved several novel therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP), though high prices may burden patients and payers. CRSwNP-specific spending varied widely by prescription drug among commercially insured patients, ranging from $7050 (EDS-FLU) to $28,324 (dupilumab). Condition-specific costs owed out-of-pocket ranged from $1036 (other drugs) to $3549 (mepolizumab).
Medical subject headings
- Sinusitis
- Nasal Polyps
- Rhinitis
- Health Expenditures
- Insurance, Health